Steve Sell: And Jamie, if I can just add to that. I think just the macro is we are investing heavily in our business in a variety of ways. I think we are the solution out there. I think we have a lead. We are trying to invest in a period of dislocation and frankly, advance that lead. And so meaningful step-up in terms of the platform support costs, a lot around technology, the amount of data that we are taking in and providing to our partners on a daily basis to help do the things that we talked about for better cost and quality has escalated dramatically when you have a much larger class, getting in front of that is a key part of it. The geo entry costs that Tim talked about. Now that’s just a function of the double the class size, but that’s a substantial investment.
And then this acquisition that we talked about. So in a variety of ways, we are trying to do things that are going to put our partners in a position to really extend their lead in their communities and attract other doctors and other patients.
Operator: Our next question comes from Whit Mayo of Bravo Securities.
WhitMayo : Tim, I was just wondering if you guys are making any changes in your patient attribution initiatives or process. It’s just anything new with the systems to ensure that you’re matching with the plans given the materiality of the membership growth in front of you? And maybe do you find that the plans are getting better with this as well. They obviously have some huge incentives to match alongside you.
Steve Sell: So Whit, it’s Steve. I can chime in on this one. We are spending a lot of time with our plans right now. We are on the phone with the Humana National team on Monday we collectively have a goal to really accelerate that period. So there’s not as much retroactivity. And so both of us are saying, what do we need to do earlier. When you have a mix shift, like you talked about between plans. Obviously, there’s more work around that. And so it’s what I would say, it’s a lot of logic, it’s a lot of process. It’s a lot of data. that’s going on to make that work happens. There’s still going to be some retroactivity through this first quarter, given the magnitude of some of those shifts. But it’s just kind of table stakes in this business. And we’ve got a great relationship with the plans, and we’re working on it.
Tim Bensley: Yes. No, I think that’s fair. I don’t think we’re doing anything new, but I would say that, that continues to be a strength of our model and one of the strengths that we bring to our partnerships, both with the payers and with our provider groups. Our ability to have a really good attribution logic and process for — obviously, it’s easy to do for HMO membership, but to be able to do that for the significant mix of PPO membership that we have is something that actually essentially makes our model work. So I wouldn’t say we’re necessarily doing anything new, but our ability to sort of leverage that core expertise that we have really makes it a lot easier for us to expand both with the national payers and with all these new regional payers that we’re bringing on.
Operator: Our next question comes from Sandy Draper from Guggenheim.
